← Back to Search

Base-editing Technology

VERVE-102 for High Cholesterol

Phase 1
Recruiting
Research Sponsored by Verve Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of HeFH or premature CAD
Females of non-childbearing potential or males
Must not have
Homozygous familial hypercholesterolemia
Active or history of chronic liver disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

"This trial is testing a new medication called VERVE-102 on patients with high cholesterol or heart disease. The medication uses a technology that targets a specific gene in the liver to lower cholesterol levels. The

Who is the study for?
This trial is for patients with familial hypercholesterolemia or premature coronary artery disease who need extra help lowering their LDL cholesterol. It's open to men and women who can't have children.
What is being tested?
VERVE-102, a new treatment using base-editing technology, is being tested. It aims to disrupt the PCSK9 gene in the liver, which should lower bad cholesterol levels. This early-phase study will check its safety and how it affects patients.
What are the potential side effects?
Since this is an early-stage trial for VERVE-102, specific side effects are not listed but may include reactions related to gene editing such as immune responses or off-target genetic effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with familial hypercholesterolemia or early-onset coronary artery disease.
Select...
I am either a male or a female who cannot become pregnant.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a genetic condition that causes very high cholesterol.
Select...
I have or had liver disease.
Select...
I am currently taking or have recently taken a PCSK9 inhibitor.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4: Single Ascending Dose EscalationExperimental Treatment1 Intervention
Participants will receive a single dose of VERVE-102.
Group II: Cohort 3: Single Ascending Dose EscalationExperimental Treatment1 Intervention
Participants will receive a single dose of VERVE-102.
Group III: Cohort 2: Single Ascending Dose EscalationExperimental Treatment1 Intervention
Participants will receive a single dose of VERVE-102.
Group IV: Cohort 1: Single Ascending Dose EscalationExperimental Treatment1 Intervention
Participants will receive a single dose of VERVE-102.

Find a Location

Who is running the clinical trial?

Verve Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
160 Total Patients Enrolled
3 Trials studying Hypercholesterolemia
160 Patients Enrolled for Hypercholesterolemia
~24 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top